옵션 체인은 다양한 행사가격과 만기일에 대한 Tilray Brands의 주식 옵션 주요 데이터를 보여줍니다. 트레이더들은 이 정보를 사용하여 잠재적 거래를 분석하고 Tilray Brands에 대한 시장 심리를 평가합니다..

Tilray Brands (NASDAQ:TLRY) 주식, 옵션 체인

Tilray Brands

Tilray is a Canadian producer that cultivates and sells medical and recreational cannabis. In 2021, legacy Aphria acquired legacy Tilray in a reverse merger and renamed itself Tilray. The bulk of its sales are in Canada and in the international medical cannabis export market. US exposure consists of CBD products and alcohol.

News

Legal

Markets

Tech

Media

BABA

NVDA

TLRY

메타 플랫폼스(NASDAQ:META)는 케임브리지 애널리티카(Cambridge Analytica)의 데이터 스캔들에 대한 미국 대법원의 항소가 기각된 후 수십억 달러 규모의 소송에 직면할 예정이다.

메타, 대법원이 CA 데이터 스캔들에 대한 항소를 기각하여 수십억 달러 규모의 소송 직면

Cannabis

Earnings

Movers

틸레이 브랜즈(NASDAQ:TLRY)는 월요일 시장 마감 후 2024 회계연도 4분기 재무 결과를 발표했다. 이번 분기의 주요 지표를 살펴보세요.

틸레이: 4분기 매출 및 EPS 예상 상회에 주가 급등, 대마초, 음료 및 웰빙의 융합을 선도

Tilray Brands Inc

AMC Entertainment Holdings Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMC#NYSE">AMC</a>) stock is spinning its wheels on Thursday despite a strong move in shares of retail darling GameStop Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GME#NYSE">GME</a>). The two often trade in sympathy, but the retail crowd may have found shinier toys <a href="https://www.benzinga.com/topic/holiday-sales">this holiday season</a>.
What To Know: Meme stock trader&nbsp;Keith Gill,&nbsp;also known as&nbsp;<a href="https://www.benzinga.com/topic/roaring-kitty" target="_blank" rel="noreferrer noopener">&#8220;Roaring Kitty,&#8221;</a>&nbsp;posted an <a href="https://x.com/TheRoaringKitty/status/1871933930963693706">image</a> of a wrapped gift in traditional Christmas colors Wednesday while markets were closed for the holiday. 
GameStop shares were up more than 5% at last check on the heels of the Roaring Kitty post, per <a href="http://pro.benzinga.com">Benzinga Pro</a>. 
Other so-called meme stocks were also getting a lift, including Koss Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KOSS#NASDAQ">KOSS</a>) and BlackBerry Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BB#NYSE">BB</a>). But AMC was trading flat to down after jumping briefly at the open. 
AMC is considered one of the original meme stocks alongside GameStop. The stock has maintained cult-like support from a group of retail traders who call themselves apes since the meme stock craze of 2021. 
AMC CEO Adam Aron has leaned into the support from retail traders. He <a href="https://x.com/CEOAdam/status/1871919103780548802">reposted</a> multiple X posts on Wednesday featuring images of apes watching movies at AMC theaters. 
Check This Out: <a href="https://www.benzinga.com/trading-ideas/movers/24/12/42679610/roaring-kittys-christmas-post-has-gamestop-rallying-7-in-overnight-trading-memecoin-connected-to-trader-also-surge">Roaring Kitty&#8217;s &#8216;Christmas&#8217; Post Has GameStop Rallying 7% In Overnight Trading — Memecoin Connected To Trader Also Surge</a>
Imax Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IMAX#NYSE">IMAX</a>) CEO Rich Gelfond also provided strong commentary on recent box office strength in an interview on CNBC&#8217;s &#8220;Squawk On The Street&#8221; Thursday morning. 
&#8220;The great thing about this time of year is every day is like a weekend &#8230; so a lot of momentum at the end of the year,&#8221; Gelfond said.
He noted that box office demand has been &#8220;really terrific&#8221; since Thanksgiving and suggested that a lot of families were visiting theaters on Christmas Eve and Christmas Day.
All of this seems to bode well for AMC, yet the stock is struggling to gain any momentum on Thursday. Instead, traders appear to guess Roaring Kitty&#8217;s next move.
Gill took a position in Chewy Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHWY#NYSE">CHWY</a>) stock earlier this year and telegraphed the move by posting a picture of a dog on X before disclosing a 6.6% stake in the pet retailer a few days later. He <a href="https://www.benzinga.com/news/24/10/41614177/roaring-kitty-puts-chewy-stock-in-the-litter-box-gamestop-shares-move-higher-after-hours">dumped</a> his entire position in September.
Meme stocks began heating up again in early December after Gill&nbsp;<a href="https://www.benzinga.com/general/social-media/24/12/42349100/gamestop-rockets-as-roaring-kitty-returns-to-x-what-does-his-tweet-signal-ahead-of-q3-earnings" target="_blank" rel="noreferrer noopener">posted an image</a>&nbsp;of a TIME magazine cover featuring a blank computer screen and a video player paused at the 1:09 mark of a 4:20-long video. His only other post since is the image of a present posted on Wednesday. 
There is a lot of speculation about what Roaring Kitty could be planning. One of the most popular guesses across Reddit&#8217;s r/WallStreetBets and Stocktwits appears to be a bet on Tilray Brands Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NASDAQ">TLRY</a>). Tilray fits into the <a href="https://www.benzinga.com/topic/420">420 theme</a> and is due to report earnings before the market opens on Jan. 9, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>. Tilray was up about 4% at last check.
GameStop shares are up about 5% over the past month and are up more than 46% over the past three months. AMC shares, on the other hand, are down about 18% over the past month and are down about 8% over a three-month period.
AMC Price Action: AMC shares were down 0.37% at $4.05 at the time of publication, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42437928/after-another-cryptic-post-lets-remember-how-roaring-kitty-managed-to-surpass-even-nancy-pelosis-enormous-wealth">After Another Cryptic Post, Let&#8217;s Remember How Roaring Kitty Managed To Surpass Even Nancy Pelosi&#8217;s Enormous Wealth</a></li>
</ul>
Photo: Shutterstock.

CHWY

IMAX

KOSS

What's Going On With AMC Entertainment Stock?

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. 
Here's the list of options activity happening in today's session: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>PFE</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/27/24</td>
<td>$26.50</td>
<td>$152.0K</td>
<td>24.2K</td>
<td>8.7K</td>
</tr>
<tr>
<td>TLRY</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$1.50</td>
<td>$34.6K</td>
<td>54.8K</td>
<td>5.9K</td>
</tr>
<tr>
<td>HIMS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$30.00</td>
<td>$195.0K</td>
<td>6.7K</td>
<td>1.8K</td>
</tr>
<tr>
<td>IOVA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$7.50</td>
<td>$41.6K</td>
<td>7.8K</td>
<td>1.7K</td>
</tr>
<tr>
<td>AVXL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>07/18/25</td>
<td>$17.00</td>
<td>$57.1K</td>
<td>1.5K</td>
<td>1.4K</td>
</tr>
<tr>
<td>LQDA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$10.00</td>
<td>$34.0K</td>
<td>1.8K</td>
<td>93</td>
</tr>
<tr>
<td>VRTX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$410.00</td>
<td>$28.2K</td>
<td>701</td>
<td>63</td>
</tr>
<tr>
<td>TMDX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$75.00</td>
<td>$33.4K</td>
<td>94</td>
<td>41</td>
</tr>
<tr>
<td>AMGN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/16/25</td>
<td>$275.00</td>
<td>$30.0K</td>
<td>29</td>
<td>24</td>
</tr>
<tr>
<td>CI</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$280.00</td>
<td>$26.1K</td>
<td>848</td>
<td>8</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These bullet-by-bullet explanations have been constructed using the accompanying table. 
• For PFE (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>), we notice a call option trade that happens to be bearish, expiring in 1 day(s) on December 27, 2024. This event was a transfer of 8000 contract(s) at a $26.50 strike. The total cost received by the writing party (or parties) was $152.0K, with a price of $19.0 per contract. There were 24292 open contracts at this strike prior to today, and today 8717 contract(s) were bought and sold. 
• Regarding TLRY (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NASDAQ">TLRY</a>), we observe a call option sweep with bullish sentiment. It expires in 22 day(s) on January 17, 2025. Parties traded 1500 contract(s) at a $1.50 strike. This particular call needed to be split into 30 different trades to become filled. The total cost received by the writing party (or parties) was $34.6K, with a price of $23.0 per contract. There were 54857 open contracts at this strike prior to today, and today 5953 contract(s) were bought and sold. 
• For HIMS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>), we notice a call option trade that happens to be bearish, expiring in 22 day(s) on January 17, 2025. This event was a transfer of 1000 contract(s) at a $30.00 strike. The total cost received by the writing party (or parties) was $195.0K, with a price of $195.0 per contract. There were 6719 open contracts at this strike prior to today, and today 1888 contract(s) were bought and sold. 
• For IOVA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IOVA#NASDAQ">IOVA</a>), we notice a call option trade that happens to be bearish, expiring in 22 day(s) on January 17, 2025. This event was a transfer of 757 contract(s) at a $7.50 strike. The total cost received by the writing party (or parties) was $41.6K, with a price of $55.0 per contract. There were 7847 open contracts at this strike prior to today, and today 1775 contract(s) were bought and sold. 
• Regarding AVXL (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVXL#NASDAQ">AVXL</a>), we observe a call option sweep with bearish sentiment. It expires in 204 day(s) on July 18, 2025. Parties traded 200 contract(s) at a $17.00 strike. This particular call needed to be split into 8 different trades to become filled. The total cost received by the writing party (or parties) was $57.1K, with a price of $285.0 per contract. There were 1543 open contracts at this strike prior to today, and today 1410 contract(s) were bought and sold. 
• Regarding LQDA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LQDA#NASDAQ">LQDA</a>), we observe a call option sweep with bearish sentiment. It expires in 386 day(s) on January 16, 2026. Parties traded 83 contract(s) at a $10.00 strike. This particular call needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $34.0K, with a price of $410.0 per contract. There were 1892 open contracts at this strike prior to today, and today 93 contract(s) were bought and sold. 
• Regarding VRTX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>), we observe a call option sweep with bullish sentiment. It expires in 22 day(s) on January 17, 2025. Parties traded 25 contract(s) at a $410.00 strike. This particular call needed to be split into 9 different trades to become filled. The total cost received by the writing party (or parties) was $28.2K, with a price of $1130.0 per contract. There were 701 open contracts at this strike prior to today, and today 63 contract(s) were bought and sold. 
• For TMDX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMDX#NASDAQ">TMDX</a>), we notice a put option sweep that happens to be bullish, expiring in 112 day(s) on April 17, 2025. This event was a transfer of 18 contract(s) at a $75.00 strike. This particular put needed to be split into 11 different trades to become filled. The total cost received by the writing party (or parties) was $33.4K, with a price of $1860.0 per contract. There were 94 open contracts at this strike prior to today, and today 41 contract(s) were bought and sold. 
• Regarding AMGN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>), we observe a call option sweep with bullish sentiment. It expires in 141 day(s) on May 16, 2025. Parties traded 23 contract(s) at a $275.00 strike. This particular call needed to be split into 9 different trades to become filled. The total cost received by the writing party (or parties) was $30.0K, with a price of $1305.0 per contract. There were 29 open contracts at this strike prior to today, and today 24 contract(s) were bought and sold. 
• For CI (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>), we notice a put option trade that happens to be bullish, expiring in 386 day(s) on January 16, 2026. This event was a transfer of 8 contract(s) at a $280.00 strike. The total cost received by the writing party (or parties) was $26.1K, with a price of $3266.0 per contract. There were 848 open contracts at this strike prior to today, and today 8 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more news on unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Options

AMGN

AVXL

Hims & Hers Health, Inc. Class A Common Stock

HIMS

IOVA

LQDA

TMDX

VRTX

10 Health Care Stocks With Whale Alerts In Today's Session

<ul>
<li>TLRY</li>
<li>NVDA</li>
<li>MSTR</li>
<li>AMD</li>
<li>TSLA</li>
<li>GOOGL</li>
<li>$BTC</li>
<li>AAPL</li>
<li>AAL</li>
<li>LUNR</li>
</ul>
<a href="https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment">https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment</a>
&nbsp;

Trading Ideas

$BTC

AAPL

GOOGL

LUNR

MSTR

TSLA

Top 10 Trending Stocks On WallStreetBets As Of December 24, 2024 (Via Swaggy Stocks)

Shares of Carbon Revolution Public Limited Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CREV#NASDAQ">CREV</a>) rose sharply during Tuesday's pre-market session after the company announced it has reached an agreement with OIC for a further $25 million in financing to <a href="https://www.benzinga.com/quote/CREV">support the ongoing liquidity of the business.</a>
Carbon Revolution shares jumped 62.4% to $6.32 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Avinger, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGR#NASDAQ">AVGR</a>) gained 138.2% to $1.53 in pre-market trading. Avinger, last week, announced it has received a Notice of Allowance for a U.S. patent titled &#8220;Catheter Device With Detachable Distal End (For The Treatment Of Peripheral Artery Disease).&#8221;</li>
<li>Tivic Health Systems, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIVC#NASDAQ">TIVC</a>) gained 107% to $0.4650 in pre-market trading after the company's CEO outlined 2025 priorities, seeing a 30% reduction in net operating loss.</li>
<li>NeueHealth, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEUE#NYSE">NEUE</a>) gained 59.2% to $6.86 in pre-market trading after the company announced it has entered into a definitive merger to be acquired for $7.33 per share.</li>
<li>Theriva Biologics, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TOVX#NYSE">TOVX</a>) rose 38.5% to $1.80 in pre-market trading after the company announced it received a notice of allowance for U.S. Patent Application No. 18.534,962 titled &#8220;Microbiome Protection from Oral Antibiotics.&#8221;</li>
<li>SES AI Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SES#NYSE">SES</a>) shares jumped 37.3% to $0.7150 in pre-market trading.</li>
<li>SEALSQ Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LAES#NASDAQ">LAES</a>) gained 35% to $6.61 in pre-market trading after jumping more than 78% on Monday.</li>
<li>Nocera, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCRA#NASDAQ">NCRA</a>) rose 32.1% to $1.22 in pre-market trading after gaining around 9% on Monday.</li>
<li>AmpliTech Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMPG#NASDAQ">AMPG</a>) gained 26.3% to $3.12 in pre-market trading after surging around 25% on Monday.</li>
<li>Tilray Brands, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NASDAQ">TLRY</a>) rose 17.5% to $1.68 in pre-market trading after gaining over 13% on Monday.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Sol-Gel Technologies Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLGL#NASDAQ">SLGL</a>) shares tumbled 42.2% to $0.9540 in pre-market trading after jumping 285% on Monday.</li>
<li>Check-Cap Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHEK#NASDAQ">CHEK</a>) declined 18.7% to $1.83 in pre-market trading after jumping around 270% on Monday.</li>
<li>KORE Group Holdings, Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KORE#NYSE">KORE</a>) fell 15% to $1.25 in pre-market trading. KORE announced NYSE acceptance of plan to regain listing compliance.</li>
<li>Nvni Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVNI#NASDAQ">NVNI</a>) fell 12.8% to $4.97 in today's pre-market trading after dipping around 34% on Monday.</li>
<li>Fifth District Bancorp, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FDSB#NASDAQ">FDSB</a>) shares dipped 12.6% to $11.00 in pre-market trading after falling 3% on Monday.</li>
<li>Tutor Perini Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TPC#NYSE">TPC</a>) dipped 12.1% to $22.01 in pre-market trading.</li>
<li>Reliance Global Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RELI#NASDAQ">RELI</a>) shares fell 11.6% to $2.75 in pre-market trading after jumping 159% on Monday.</li>
<li>Helius Medical Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSDT#NASDAQ">HSDT</a>) fell 6.8% to $0.8950 in pre-market trading after gaining over 5% on Monday.</li>
<li>Lindblad Expeditions Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIND#NASDAQ">LIND</a>) shares fell 9.8% to $11.01 in pre-market trading.</li>
<li>Brookfield Infrastructure Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BIPC#NYSE">BIPC</a>) fell 8.7% to $35.01 in pre-market trading.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/12/42648003/how-to-earn-500-a-month-from-qualcomm-stock-2">How To Earn $500 A Month From Qualcomm Stock</a></li>
</ul>

Pre-Market Outlook

AMPG

AVGR

BIPC

CHEK

CREV

FDSB

HSDT

KORE

LAES

LIND

NCRA

NEUE

NVNI

RELI

SLGL

TIVC

TOVX

Why Carbon Revolution Shares Are Trading Higher By Around 62%; Here Are 20 Stocks Moving Premarket

<ul>
<li>TLRY</li>
<li>TSLA</li>
<li>AMD</li>
<li>NVDA</li>
<li>LUNR</li>
<li>PLTR</li>
<li>CORN</li>
<li>MSTR</li>
<li>KULR</li>
<li>QQQ</li>
</ul>
Data from <a href="https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment">https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment</a>
&nbsp;

CORN

KULR

PLTR

Top 10 Trending Stocks On WallStreetBets As Of December 23, 2024 (Via Swaggy Stocks)

Tilray Brands's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NYSE">TLRY</a>) short percent of float has fallen 11.86% since its last report. The company recently reported that it has 108.65 million shares sold short, which is 12.11% of all regular shares that are available for trading. Based on its trading volume, it would take traders 4.56 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Tilray Brands Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734467421_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Tilray Brands has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Tilray Brands's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Tilray Brands's peer group average for short interest as a percentage of float is 15.12%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

How Is The Market Feeling About Tilray Brands?

AAWH

ALEAFIA HEALTH INC ORD by Aleafia Health Inc.

ALEAF

AUSAF

AVTBF

AYRWF

BBRRF

BHHKF

BLOZF

BMMJ

CANN

CBDY

CBMJ

CANNABIS WHEATON INCOME by Cannabis Wheaton Income Corp.

CBWTF

CHOOF

CLSH

CLVR

CNBS

CNBX

CNGGF

CNPOF

CNTMF

CNVCF

CPHRF

CRLBF

CRON

CURALEAF HLDGS INC by Curaleaf Hldgs Inc.

CURLF

CURE PHARMA HLDG CORP by CURE Pharmaceutical Holding Corp.

CURR

CVHIF

CVSI

CWBHF

CANNIBIS GROWTH OPTY CORP by Cannabis Growth Opportunity Corp.

CWWBF

CXXIF

ELLXF

EMOR

ETST

EVIO

FFLWF

FFNTF

FUTURE FARM TECHNOLOGIES by Future Farm Technologies Inc.

FFRMF

FLGC

FLOOF

FLWPF

FINCANNA CAPITAL CORP by Fincanna Capital Corp.

FNNZF

FUAPF

GABRIELLAS KITCHEN INC by Gabriella's Kitchen Inc.

GABLF

GBHPF

GENE

GHBWF

GLASF

GNLN

GRAMF

GRNH

GRWG

GREEN SPIRIT INDUSTRIES by Green Spirit Industries Inc.

GSRX

GTBIF

HBOSF

HEMP

HERTF

HHPHF

HMLSF

IIPR

INCR

INLB

ISODIOL INTERNATIONAL ORD by Isodiol International Inc.

ISOLF

ITHUF

IVITF

JWCAF

KALY

KAYS

KHIRON LIFE SCIENCES CORP by Khiron Life Sciences Corp.

KHRNF

LEAFBUYER TECHNOLOGIES by Leafbuyer Technologies, Inc.

LBUY

LFCOF

LFLY

LIFD

LMLLF

LNLHF

LOVFF

LRSNF

LVRLF

LXLLF

MAPS

MGCLF

MGWFF

MJNE

MJUS

MMNFF

MPXOF

MRMD

NDVAF

NOBDF

NWVCF

OILFF

PHOT

PKPH

Dropbox shares are trading higher after the company secured a $2 billion term loan facility led by Blackstone, authorized a $1.2 billion share repurchase program, and stated it expects to meet or exceed Q4 and FY 2024 guidance.

Tilray Brands Announced A New Holiday Campaign Spotlighting A Series Of Cannabis-infused Beverages From Two Of Its Renowned Beverage Brands, XMG And Mollo

The rise of hemp-derived cannabinoids like Delta-8 THC is reshaping the cannabis landscape in the U.S. Touted as legal alternatives to Delta-9 THC, these products have surged in popularity, <a href="https://www.benzinga.com/markets/cannabis/24/08/40561082/delta-8-thc-exposure-is-lower-in-states-where-recreational-marijuana-is-legal-say-researchers-ba">particularly</a> in states where recreational cannabis remains prohibited.
The unregulated nature and potential health risks of these products have ignited fierce debates among policymakers and industry stakeholders. In an exclusive interview with Benzinga, Dr. Carl L. Hart, a renowned neuroscientist, author and the Ziff professor of psychology at Columbia University, offered a stark critique of the current regulatory framework.
<h3 class="wp-block-heading">The Multi-Billion Consequence Of A Legal Loophole</h3>
Delta-9 THC, the primary psychoactive compound in cannabis, <a href="https://www.benzinga.com/markets/cannabis/24/02/36916329/is-marijuana-a-controlled-substance-wait-what-is-a-controlled-substance">remains federally illegal</a>, though several states have legalized it.
This regulatory gray area was further complicated by the 2018 Farm Bill, which <a href="https://www.benzinga.com/markets/cannabis/24/07/39783607/how-hemp-became-americas-loophole-for-legal-highs">legalized hemp and its derivatives</a>, provided they contain less than 0.3% Delta-9 THC by dry weight. This created a loophole that allowed hemp-derived <a href="https://norml.org/marijuana/fact-sheets/normls-guide-to-delta-8-and-other-novel-cannabinoids/">cannabinoids</a> to flourish, offering effects similar to marijuana but sidestepping federal regulation.
As a result, products like hemp-THC gummies, <a href="https://www.benzinga.com/markets/cannabis/24/08/40418137/industrial-hemps-14b-projected-growth-an-investment-opportunity-too-good-to-miss">beverages</a> and vape cartridges have surged in popularity, often marketed as legal alternatives to cannabis. Delta-8 THC products alone generated an estimated $1.2 billion in sales in 2023, <a href="https://www.benzinga.com/government/regulations/24/11/41851368/hemp-market-surge-how-new-regulations-could-impact-growth">according</a> to Cannabis Business Times.
However, despite the growth of the hemp-derived market, major cannabis companies like Curaleaf Holdings (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CURLF#OTC">CURLF</a>), Canopy Growth (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGC#NASDAQ">CGC</a>) and Tilray Brands (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NASDAQ">TLRY</a>) are <a href="https://www.benzinga.com/markets/cannabis/24/07/39820619/strategy-shift-in-the-works-are-cannabis-giants-getting-into-the-hemp-derived-thc-market">expanding into this space</a>, Hart sees it as indicative of confusion rather than progress.
The core issue, according to Hart, is the <a href="https://www.benzinga.com/markets/cannabis/24/09/40878965/should-delta-8-thc-be-regulated-its-a-total-free-for-all-says-industry-expert">unregulated production</a> of these cannabinoids. Since many hemp-derived cannabinoids are synthesized from <a href="https://www.benzinga.com/markets/cannabis/24/01/36584043/real-weed-or-a-lab-high-delta-8-and-delta-9-thc-explained">hemp-extracted CBD</a>, the chemical conversion process can introduce contaminants, leading to inconsistent product quality.
&#8220;It has less to do with the compounds and more to do with the situation under which these compounds are being produced,&#8221; he explained.
<h3 class="wp-block-heading">Public Health Risks Of Unregulated Products</h3>
Hart stressed that the rise of hemp-derived cannabinoids mirrors past public health crises linked to drug prohibition. Drawing a parallel to <a href="https://www.benzinga.com/markets/cannabis/22/08/28416682/study-dangerous-synthetic-cannabinoids-poisonings-are-less-common-in-legal-cannabis-states">synthetic cannabinoids like Spice and K2</a>, he explained how banning substances without offering safe alternatives drives consumers toward unregulated and <a href="https://www.benzinga.com/markets/cannabis/24/04/38151776/93-of-smokable-hemp-exceeds-legal-thc-limit-government-funded-study-finds">often dangerous options</a>.
"Whenever you have unregulated markets… potential harms go away when you regulate the market," he said, likening the current scenario to the issues faced during alcohol prohibition. He also highlighted parallels with the <a href="https://www.benzinga.com/markets/cannabis/24/09/40990399/fentanyl-laced-with-toxic-chemical-btmps-raises-alarms-nationwide-experts-warn-of-danger">fentanyl</a> crisis, where unregulated drug markets <a href="https://www.benzinga.com/markets/cannabis/24/07/39672165/could-heroin-be-preventing-the-spread-of-fentanyl-in-spain">led to dangerous substitutions</a>.&nbsp;
Federal cannabis legalization, he says, would mitigate these risks by providing safe, regulated products.
<h3 class="wp-block-heading">Economic And Political Incentives Sustain Prohibition</h3>
The persistence of federal <a href="https://www.benzinga.com/markets/cannabis/24/02/36310179/marijuanas-prohibition-promotes-unregulated-weed-use-study-finds">cannabis prohibition</a>, despite evidence of its harm to public health, reflects deep-rooted economic interests, according to Hart. He pointed to the financial incentives that fuel resistance to reform.
"Law enforcement benefits. Not only law enforcement. Science benefits. Homeland Security benefits. The Drug Enforcement Agency benefits," he said. These institutions, he argued, have little motivation to support policies that could reduce their funding, highlighting their interest in maintaining prohibitionist policies.
<ul>
<li>Get Benzinga&#8217;s exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter <a href="https://newsletteremail.benzinga.com/subscribe">here</a>. If you&#8217;re serious about the business, you can&#8217;t afford to miss out.</li>
</ul>
Moreover, the political influence of the hemp industry further complicates the landscape. For instance, in Florida, <a href="https://www.benzinga.com/markets/cannabis/24/11/41726320/hemp-donations-fuel-desantis-and-florida-gops-charge-against-weed-legalization-new-findings">hemp companies donated over $500,000</a> to Governor Ron DeSantis and the state's GOP to oppose Amendment 3, which sought to legalize adult-use cannabis.
The amendment fell <a href="https://www.benzinga.com/markets/cannabis/24/11/41763514/florida-rejects-cannabis-legalization-amendment-supported-by-trump-detested-by-desantis">short</a> and hemp businesses, wary of competition from a regulated marijuana industry, succeeded in maintaining their market dominance undisturbed.
<h3 class="wp-block-heading">Fragmented State Hemp Regulations Add To The Problem</h3>
Meanwhile, inconsistent state regulations exacerbate the challenges posed by unregulated hemp products. States like California, Louisiana and South Dakota have <a href="https://www.benzinga.com/markets/cannabis/24/07/39610764/intoxicating-hemp-products-face-regulatory-crackdown-across-multiple-states">imposed</a> strict regulations or outright bans on hemp-derived THC, attempting to close loopholes.&nbsp;
These measures have been partly prompted by concerns over <a href="https://www.benzinga.com/markets/cannabis/24/07/39828962/fda-accuses-companies-of-marketing-cannabis-products-to-children-amid-debate-on-hemp-cannabinoid">misleading marketing tactics</a>, including products that resemble children&#8217;s snacks, raising alarms about potential risks to minors.
Read Also: <a href="https://www.benzinga.com/government/regulations/24/11/41851368/hemp-market-surge-how-new-regulations-could-impact-growth">Hemp Market Surge: How New Regulations Could Impact Growth</a>
Furthermore, these state-level bans also create unintended consequences. They impact <a href="https://www.benzinga.com/markets/cannabis/24/09/41051849/californias-hemp-restrictions-could-stifle-broader-access-to-therapeutic-products-expert-warns">reputable producers</a> and <a href="https://www.benzinga.com/markets/cannabis/24/09/40906131/this-is-life-or-death-families-of-disabled-children-panic-over-gov-newsoms-hemp-cbd-ban-and-eval">CBD users</a> who rely on consistent, reliable hemp products. Hart criticized this fragmented regulatory approach and emphasized the need for federal oversight, calling for a <a href="https://www.benzinga.com/markets/cannabis/24/09/40833963/expert-calls-for-a-united-hemp-and-cannabis-front-industries-should-collaborate-and-push-for-fed">unified framework</a> that ensures consistency across states.
<h3 class="wp-block-heading">Disproportionate Impact On Marginalized Communities</h3>
The regulatory chaos surrounding hemp-derived cannabinoids also highlights broader inequities in U.S. drug policy. Hart emphasized that Black and Latino populations remain <a href="https://www.benzinga.com/markets/cannabis/23/09/34826776/treating-drug-users-as-criminals-only-makes-matters-worse-says-un-official-latest-global-cannabi">disproportionately affected</a> by arrests, fines and imprisonment for drug-related offenses, despite similar cannabis use rates across demographics.
His perspective challenges investors and industry players to acknowledge the larger context. The unregulated hemp cannabinoid surge reflects a systemic malfunction, one fueled by inconsistent laws and profit-driven deterrents to genuine reform.
<h3 class="wp-block-heading">Toward Evidence-Based Drug Policy Reform</h3>
As debates around hemp-derived cannabinoids intensify, Hart remains firm in his belief that straightforward solutions are available.
Although he expressed skepticism that the U.S. will embrace <a href="https://www.benzinga.com/markets/cannabis/23/06/33000216/united-nations-calls-for-end-to-global-war-on-drugs-health-and-human-rights-instead-of-punishmen">evidence-based policies</a> anytime soon, Hart insists that the facts remain unchanged: properly regulated markets lead to safer products, safeguard user rights and reduce harm across the board.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/government/regulations/24/11/42068539/billion-dollar-strike-farm-bill-amendment-could-change-the-hemp-industry">Billion-Dollar Strike: Farm Bill Amendment Could Change The Hemp Industry</a></li>
</ul>
Photo credits: <a href="https://www.flickr.com/photos/fronteirasweb/51713751348/in/photostream/">Flickr</a> &#8211; Fronteiras do Pensamento / Greg Salibian

Regulations

Exclusives

Interview

EXCLUSIVE: Drug Expert Dr. Carl Hart Slams Cannabis Prohibition Amid Hemp-THC Surge

In a recent note, senior analyst Pablo Zuanic digs into the financial standing and valuation of Village Farms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VFF#NASDAQ">VFF</a>), the <a href="https://www.benzinga.com/markets/cannabis/24/11/41726679/village-farms-is-only-cannabis-operator-selected-to-represent-weed-industry-at-dea-rescheduling-">only cannabis company </a>anointed by the Drug Enforcement Agency (DEA) as one of the 25 DPs ("designated participants") in the <a href="https://www.benzinga.com/24/12/42270539/dea-live-hearing-on-marijuana-rescheduling-what-to-expect">administrative hearing</a> for the rescheduling of cannabis to Schedule III.
According to Zuanic, the company experienced temporary sales disruptions in the second half of the year, primarily due to stockouts caused by strong first-half demand. These disruptions are expected to normalize by the first quarter of 2025. Although the overall demand for Canadian recreational cannabis is <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41599546/canadas-cannabis-market-goes-cold-pot-prices-hit-bottom-why-top-producers-are-losin">slowing down</a>, Village Farms has been able to increase prices for some SKUs.
<ul>
<li>Get Benzinga&#8217;s exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter&nbsp;<a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. You can't afford to miss out if you&#8217;re serious about the business.</li>
</ul>
<h3 class="wp-block-heading">Global Reach And Scale</h3>
Beyond Canada, Village Farms is focused on growing its international business, particularly in Germany, <a href="https://www.benzinga.com/topic/australia-cannabis">Australia</a>, and the UK. It plans to allocate Canadian production based on return on investment (ROI) and may consider minority investments in <a href="https://www.benzinga.com/general/market-summary/24/11/42126680/german-cannabis-20-tons-10m-grams-and-thats-only-0-3-of-the-market-whats-missing">international markets</a>.
The company will prioritize its branded domestic cannabis business and<a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/07/39609582/europe-is-turning-cash-flow-positive-well-see-what-happens-in-the-u-s-largest-canna"> international sales</a>. It will reduce B2B sales for domestic purposes and allocate more output to its branded products.
Branded sales margins are recovering to the 30-40% range and B2B margins are increasing due to higher prices and increased overseas demand. Zuanic noted approximately one-third of domestic B2B sales are re-exported to <a href="https://www.benzinga.com/topic/germany-cannabis">Germany</a>.
Read Also:<a href="https://www.benzinga.com/government/regulations/24/11/42198793/prohibitionist-group-denies-collusion-allegations-ahead-of-dea-cannabis-rescheduling-hearing"> Prohibitionist Group Denies Collusion Allegations Ahead Of DEA Cannabis Rescheduling Hearing</a>
<h3 class="wp-block-heading">Market Share </h3>
Hifyre data for October and November shows a sequential improvement in the Canadian recreational cannabis market, with a year-over-year growth of 6.7%. However, Village Farms experienced a deceleration to 1% year-over-year growth.
<ul>
<li>Among the top 10 players, Tilray (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NASDAQ">TLRY</a>) (-21%), Decibel (OTC:<a class="ticker" href="https://www.benzinga.com/stock/DBCCF#OTC">DBCCF</a>) (-23%), and Canopy Growth (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGC#NASDAQ">CGC</a>) (-21%) experienced a decline in growth. On the other hand, Cannara (OTC:<a class="ticker" href="https://www.benzinga.com/stock/LOVFF#OTC">LOVFF</a>) (+67%) and WeedMD (+23%) saw significant growth.&nbsp;</li>
<li>OGI (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OGI#NASDAQ">OGI</a>) (+13%), Auxly (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CBWTF#OTC">CBWTF</a>) (+33%), Motif (+10%), and Cronos Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRON#NASDAQ">CRON</a>) (+4%) also exhibited positive growth.</li>
<li>In terms of November market share, Tilray (TLRY) (9.1%) held the largest share, followed by OGI (7.0%), VFF (6.2%), Auxly (5.6%), Motif (5.3%), Cronos Group (5.1%), Decibel (4.7%), Cannara (4.0%), WeedMD (2.9%), and Canopy Growth (2.3%).</li>
</ul>
Read Also:<a href="https://www.benzinga.com/markets/cannabis/24/11/41805907/village-farms-quarterly-revenue-grows-20-yoy-as-the-cannabis-company-doubles-international-sales"> Village Farms Quarterly Revenue Grows 20% YoY As The Cannabis Company Doubles International Sales</a>
<h3 class="wp-block-heading">Valuation </h3>
Zuanic<a href="https://zuanicgroup.com/"> argues</a> that Village Farms' stock is undervalued due to its complex business model and gradual growth strategy, despite its strong performance in the Canadian cannabis market, international expansion and potential US opportunities. 
He calculates the company&#8217;s enterprise value (EV) to be around US$120 million. This valuation implies a low multiple of 0.4x current sales estimates and 5.6x EBITDA.
Zuanic says the market is not fully recognizing the value of VFF&#8217;s assets. 
If we strip out the value of the produce business, US CBD operations and <a href="https://www.benzinga.com/topic/texas-cannabis">Texas</a> greenhouses, Zuanic suggests that the remaining valuation for the cannabis unit is around US$19 million, or 0.1x estimated 2025 sales and 3x EBITDA. This is significantly lower than the<a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41811378/aurora-vs-canopy-tilray-which-nasdaq-listed-cannabis-stock-offers-the-best-growth-p"> valuations of other major cannabis companies</a> like <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41613366/beyond-beer-tilrays-1-67-billion-market-play-is-this-cannabis-giant-still-a-smart-b">Tilray</a> and Aurora Cannabis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACB#NASDAQ">ACB</a>).
Read Next: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41925770/three-paths-to-cannabis-profits-village-farms-green-thumb-and-jushi-show-divergent-">Three Paths To Cannabis Profits: Village Farms, Green Thumb, And Jushi Show Divergent Strategies—Which Will Deliver?</a>

Analyst Color

Guidance

Eurozone

Retail Sales

Global

Analyst Ratings

DBCCF

Are You Missing Out On This NASDAQ-Listed Weed Stock? Low-Cost Model Meets European Demand

Decibel Cannabis (OTC:<a class="ticker" href="https://www.benzinga.com/stock/DBCCF#OTC">DBCCF</a>) is poised for significant growth, as outlined in a recent report by Zuanic &amp; Associates, which highlights Decibel&#8217;s robust cash flow generation as a key strength. 
With a projected free cash flow (FCF) of $20 million for 2025, the company boasts a significant FCF yield of 54%.&nbsp;
"With a leading franchise in Canadian pre-rolls (the category is as big as Flower in Canada rec now)&#8230;we believe Decibel should trade more in line with the larger market cap LP stocks (especially with debt leverage projected below 1.4x for next year)," senior analyst <a href="https://www.benzinga.com/topic/pablo-zuanic">Pablo Zuanic</a> wrote in the report.&nbsp;
<ul>
<li>Get Benzinga&#8217;s exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter&nbsp;<a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. You can't afford to miss out if you&#8217;re serious about the business.</li>
</ul>
<h3 class="wp-block-heading">Market Trends, Decibel's Performance</h3>
The <a href="https://www.benzinga.com/topic/canada-cannabis">Canadian recreational cannabis market</a> saw an improvement in October and November, with a year-over-year increase of 6.7%. However, Decibel continued to experience significant <a href="https://www.benzinga.com/24/11/42137701/canadian-cannabis-co-decibel-reports-12-yoy-drop-in-q3-revenue-but-increases-gross-margin-to-53">sales declines</a>, dropping by 23% year-over-year.
While other major players like Tilray (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NASDAQ">TLRY</a>) and Canopy Growth (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGC#NASDAQ">CGC</a>) also experienced sales declines, companies like Auxly (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CBWTF#OTC">CBWTF</a>) and Cannara (OTC:<a class="ticker" href="https://www.benzinga.com/stock/LOVFF#OTC">LOVFF</a>) showed substantial growth.
In terms of market share, Tilray maintained the top position, followed by Organigram (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OGI#NASDAQ">OGI</a>) and Village Farms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VFF#NASDAQ">VFF</a>). Decibel held a 4.7% market share in November.
<ul>
<li>Pre-rolls: Decibel&#8217;s core-infused<a href="https://www.benzinga.com/topic/pre-rolls"> pre-roll segment</a>, while still a significant contributor to revenue, has seen a decline in market share. "Over 97% of Decibel pre-roll sales come from the infused segment (3Q24), where Decibel has seen share erosion; after peaking at 57% in 2Q23, this was 35% in 3Q24 (1Q24 48%; 2Q24 41%)," reads <a href="https://zuanicgroup.com/">Zuanic's report</a>.&nbsp;</li>
</ul>
<ul>
<li>Vapes: Decibel&#8217;s total <a href="https://www.benzinga.com/topic/vapes">vape share</a> fell to 9.7% in 3Q24 from 11.8% in 3Q23, although the company has adapted well to the growing AIO segment. "Decibel has adapted well in AIOs now 29% of its vape sales and is #3 in the AIO segment with a 13% share," Zuanic noted.&nbsp;</li>
</ul>
Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/10/41600492/decibel-acquires-agmedica-announces-private-placement-and-third-quarter-guidance">Decibel Acquires AgMedica, Announces Private Placement And Third Quarter Guidance</a>
<h3 class="wp-block-heading">Strategic Acquisition</h3>
The <a href="https://www.benzinga.com/news/financing/24/11/42164794/decibel-cannabis-raises-1-18m-secures-capital-for-agmedica-bioscience-integration">acquisition of AgMedica is a strategic move</a> that will significantly enhance Decibel&#8217;s market position and growth prospects. By expanding its product portfolio, distribution network, and market share, Decibel aims to capitalize on the growing Canadian cannabis market. Key benefits include:
<ul>
<li>Expanded Product Range: AgMedica brings a diverse range of products, including flowers, pre-rolls, edibles, and concentrates.</li>
<li>Enhanced Distribution Network: The acquisition will expand Decibel&#8217;s reach, allowing it to tap into new markets and customer segments.</li>
<li>Strengthened Market Position: By combining the strengths of both companies, Decibel aims to solidify its position as a leading player in the Canadian cannabis market.</li>
</ul>
Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/12/42297466/decibel-receives-final-tsx-venture-exchange-acceptance-for-agmedica-acquisition-and-debenture-conversion">Decibel Receives Final TSX Venture Exchange Acceptance For AgMedica Acquisition And Debenture Conversion</a>
<h3 class="wp-block-heading">Zuanic's Thesis </h3>
For Zuanic, Decibel offers a compelling investment opportunity due to its financial position and growth prospects. With a projected FCF of $20 million for 2025, the stock offers a significant FCF yield of 54%.&nbsp;
Additionally, its low valuation multiples of 0.5x sales and 2.8x EBITDA make it an attractive investment. "Although we do not set price targets, at 1-2x our CY26 sales estimates, the stock could be 6-10x higher by Dec'25 vs. current levels," Zuanic concluded.&nbsp;
Read Next: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41599546/canadas-cannabis-market-goes-cold-pot-prices-hit-bottom-why-top-producers-are-losin">Canada&#8217;s Cannabis Market Goes Cold, Pot Prices Hit Bottom: Why Top Producers Are Losing Ground</a>

Market Summary

Penny Stocks

Decibel Cannabis: One Acquisition Could Be The Key To Unlocking $20M In Cash Flow

Comments

Tilray Brands

Tilray Brands (TLRY) 옵션

Tilray Brands (NASDAQ:TLRY) 주식, 옵션 체인

뉴스

파트너 / 기고자

벤징가 글로벌